Form 4: SpringWorks Therapeutics Director, Daniel Lynch, Receives Stock Grant

Director Daniel Lynch acquired 10,060 shares of SpringWorks Therapeutics stock through a restricted stock unit (RSU) grant.

Summary

• Daniel Lynch, a director at SpringWorks Therapeutics, received a grant of 10,060 shares of common stock on May 14, 2025.
• The grant was in the form of restricted stock units (RSUs) under the company's Amended and Restated Non-Employee Director Compensation Policy.
• These RSUs will vest fully on the earlier of May 14, 2026, or the date of the next annual meeting of stockholders, contingent upon continued service to the Issuer.

Sentiment

Score: 7

Explanation: The document reflects a standard equity grant to a director, indicating a positive alignment of interests. It's a routine event, but contributes to a stable outlook.

Positives

• The grant of RSUs aligns the director's interests with those of the shareholders, incentivizing continued service and contribution to the company's success.

Future Outlook

The director's continued service is tied to the vesting of the RSUs, suggesting an ongoing commitment to the company.

Industry Context

Equity grants to non-employee directors are a common practice to align their interests with those of the company and its shareholders.

Stakeholder Impact

• Shareholders: The equity grant aligns the director's interests with shareholder value.
• Director: The grant provides additional compensation and incentivizes continued service.

Key Dates

Keywords

SpringWorks Therapeutics, Director, Daniel Lynch, Stock Grant, RSU, Restricted Stock Units, Equity Compensation, Beneficial Ownership